Screen the A10 antibody for off-target binding to plasma membrane proteins and secreted proteins

This is a Firm Fixed Priced purchase order. NCI solicited and negotiated directly with Charles River Discovery Research Services UK Limited. The National Cancer Institute (NCI) has a program to use an antibody called, 'A10' to target cancer cells that have a lot of the epidermal growth factor receptor on their cell surface. While this antibody has been extensively tested and characterized it is not known if it also binds any other cell surface proteins. The contractor shall perform an off-target screen on an NCI antibody and report back on any problematic interactions that could predict a serious side effect should the antibody be given to a cancer patient. The A10 is NOT known to bind other cell surface proteins or secreted proteins but this needs to be addressed in the off-target screen.